23.88
price up icon5.43%   1.23
after-market Dopo l'orario di chiusura: 23.88
loading
Precedente Chiudi:
$22.65
Aprire:
$22.61
Volume 24 ore:
669.37K
Relative Volume:
0.91
Capitalizzazione di mercato:
$693.38M
Reddito:
$17.16M
Utile/perdita netta:
$-163.62M
Rapporto P/E:
-3.9276
EPS:
-6.08
Flusso di cassa netto:
$-121.61M
1 W Prestazione:
+2.75%
1M Prestazione:
+9.24%
6M Prestazione:
+78.74%
1 anno Prestazione:
-0.25%
Intervallo 1D:
Value
$22.43
$24.69
Intervallo di 1 settimana:
Value
$21.87
$24.86
Portata 52W:
Value
$12.21
$41.31

Anaptysbio Inc Stock (ANAB) Company Profile

Name
Nome
Anaptysbio Inc
Name
Telefono
858-362-6295
Name
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Name
Dipendente
136
Name
Cinguettio
@anaptysbio
Name
Prossima data di guadagno
2024-11-08
Name
Ultimi documenti SEC
Name
ANAB's Discussions on Twitter

Confronta ANAB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ANAB
Anaptysbio Inc
23.88 693.38M 17.16M -163.62M -121.61M -6.08
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-04 Aggiornamento H.C. Wainwright Neutral → Buy
2025-02-04 Iniziato Wolfe Research Outperform
2024-12-11 Downgrade H.C. Wainwright Buy → Neutral
2024-12-02 Downgrade BTIG Research Buy → Neutral
2024-07-22 Iniziato H.C. Wainwright Buy
2024-07-19 Aggiornamento JP Morgan Neutral → Overweight
2024-04-16 Iniziato Leerink Partners Outperform
2024-04-11 Iniziato Wells Fargo Overweight
2024-03-12 Aggiornamento Wedbush Neutral → Outperform
2024-02-26 Iniziato BTIG Research Buy
2024-02-21 Iniziato Stifel Buy
2024-02-16 Iniziato Piper Sandler Overweight
2023-05-22 Aggiornamento JP Morgan Underweight → Neutral
2023-05-18 Iniziato TD Cowen Outperform
2023-01-06 Downgrade Raymond James Outperform → Mkt Perform
2022-11-01 Aggiornamento Guggenheim Neutral → Buy
2022-09-19 Ripresa H.C. Wainwright Buy
2022-09-13 Downgrade Truist Buy → Hold
2022-09-01 Iniziato Raymond James Outperform
2022-03-22 Downgrade Guggenheim Buy → Neutral
2021-06-22 Iniziato H.C. Wainwright Buy
2021-05-21 Iniziato UBS Neutral
2021-03-16 Aggiornamento Truist Hold → Buy
2021-03-09 Downgrade Wedbush Outperform → Neutral
2021-03-08 Downgrade JP Morgan Overweight → Underweight
2021-02-11 Aggiornamento JP Morgan Underweight → Overweight
2020-10-27 Aggiornamento Wedbush Neutral → Outperform
2020-10-14 Aggiornamento Guggenheim Neutral → Buy
2019-11-08 Downgrade JP Morgan Overweight → Underweight
2019-11-08 Downgrade Jefferies Buy → Hold
2019-11-08 Downgrade SunTrust Buy → Hold
2019-11-08 Downgrade Wedbush Outperform → Neutral
2019-06-21 Downgrade Credit Suisse Outperform → Neutral
2019-06-21 Downgrade Stifel Buy → Hold
2018-12-20 Iniziato H.C. Wainwright Buy
2018-11-21 Iniziato JP Morgan Overweight
2018-07-19 Iniziato Credit Suisse Outperform
2018-04-04 Downgrade RBC Capital Mkts Outperform → Sector Perform
2018-03-27 Reiterato Stifel Buy
2018-03-06 Reiterato Stifel Buy
2018-02-15 Reiterato SunTrust Buy
2018-01-23 Reiterato Credit Suisse Outperform
2017-11-15 Iniziato SunTrust Buy
2017-11-09 Iniziato Jefferies Buy
2017-10-11 Reiterato RBC Capital Mkts Outperform
2017-09-15 Iniziato RBC Capital Mkts Outperform
Mostra tutto

Anaptysbio Inc Borsa (ANAB) Ultime notizie

pulisher
Jun 18, 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Holdings Trimmed by Bank of America Corp DE - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Assenagon Asset Management S.A. Sells 89,273 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

Jun 18, 2025
pulisher
Jun 17, 2025

AnaptysBio Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 17, 2025
pulisher
Jun 12, 2025

FMR LLC Significantly Reduces Stake in AnaptysBio Inc - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Stocks With Rising Relative Price Strength: AnaptysBio - Investor's Business Daily

Jun 12, 2025
pulisher
Jun 11, 2025

JPMorgan Sees AnaptysBio (ANAB) as Undervalued Due to Rosnilimab - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now - simplywall.st

Jun 11, 2025
pulisher
Jun 10, 2025

New RA Drug Shown to Work, Be Safe - streetwisereports.com

Jun 10, 2025
pulisher
Jun 10, 2025

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential (NASDAQ:ANAB) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 09, 2025

ANAB Schedules June 9 Conference Call with JPMorgan | ANAB Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $42.38 - MarketBeat

Jun 09, 2025
pulisher
Jun 09, 2025

AnaptysBio (NASDAQ:ANAB) Shares Up 9.1%Should You Buy? - MarketBeat

Jun 09, 2025
pulisher
Jun 08, 2025

AnaptysBio (NASDAQ:ANAB) Trading Down 4.5%Time to Sell? - MarketBeat

Jun 08, 2025
pulisher
Jun 08, 2025

AnaptysBio (NASDAQ:ANAB) Upgraded by HC Wainwright to "Buy" Rating - MarketBeat

Jun 08, 2025
pulisher
Jun 07, 2025

AnaptysBio (NASDAQ:ANAB) Shares Gap UpHere's What Happened - MarketBeat

Jun 07, 2025
pulisher
Jun 06, 2025

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement (NASDAQ:ANAB) - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Squarepoint Ops LLC - MarketBeat

Jun 05, 2025
pulisher
Jun 05, 2025

TD Cowen reiterates Buy rating on AnaptysBio stock following updated trial data - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

AnaptysBio (NASDAQ:ANAB) Upgraded to “Buy” at HC Wainwright - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

AnaptysBio (ANAB) Shares Drop Amid Trial Data Missteps - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

HC Wainwright & Co. Upgrades AnaptysBio (LSE:0HFQ) - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

J&J hurts AnaptysBio with anti-inflammatory data (ANAB:NASDAQ) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio (ANAB) Reveals Promising Phase 2b Results in Rheumato - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in rheumatoid arthritis - Endpoints News

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright upgrades AnaptysBio stock on positive trial data By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

Anaptys stock gains on arthritis drug data (ANAB:NASDAQ) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio’s Rosnilimab Shows ‘Best-in-Disease’ Profile in Phase 2b RA Trial - Insider Monkey

Jun 04, 2025
pulisher
Jun 04, 2025

Stifel analysts reiterate Buy rating for AnaptysBio stock after RA study - Investing.com UK

Jun 04, 2025
pulisher
Jun 04, 2025

HC Wainwright & Co. Upgrades AnaptysBio (ANAB) - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio (ANAB) Stock Upgraded by HC Wainwright & Co. with New - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio (ANAB) Stock Upgraded by HC Wainwright & Co. with New Target Price | ANAB Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

HC Wainwright Upgrades AnaptysBio to Buy From Neutral, $38 Price Target - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Stifel Reiterates Buy Rating on AnaptysBio (ANAB) - StreetInsider

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio (ANAB) Gets Boost from Positive Phase 2 Trial Data | ANAB Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio reports promising Phase 2b trial results for RA drug By Investing.com - Investing.com India

Jun 04, 2025
pulisher
Jun 04, 2025

AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering - Investing.com India

Jun 04, 2025
pulisher
Jun 03, 2025

Transcript : AnaptysBio, Inc.Special Call - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

AnaptysBio Reports Positive Phase 2b Trial Results - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

AnaptysBio Reports Durable Responses, Favorable Safety for Rosnilimab in Arthritis Trial - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

AnaptysBio (ANAB) Reports Promising Results for Rosnilimab in Rheumatoid Arthritis | ANAB Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Anaptys Announces Positive Rosnilimab Data Updated Through Six M - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

AnaptysBio reports promising Phase 2b trial results for RA drug - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

New Rheumatoid Arthritis Drug Achieves JAK-Like Efficacy with Better Safety Profile in Phase 2b Trial - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

Millennium Management LLC Sells 185,049 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World

Jun 03, 2025

Anaptysbio Inc Azioni (ANAB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Anaptysbio Inc Azioni (ANAB) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
RENTON HOLLINGS
Director
Jun 18 '25
Sale
23.97
3,015
72,270
4,965
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):